Supercharged T-Cells take on blood cancers in new trial

NCT ID NCT01853631

First seen Jan 06, 2026 · Last updated May 16, 2026 · Updated 16 times

Summary

This early-phase study tests a new type of immunotherapy for people with advanced B-cell lymphoma or leukemia that has returned or not responded to standard treatment. Researchers take a patient's own T-cells (a type of immune cell), add a special receptor that targets a protein called CD19 found on cancer cells, and also add extra stimulatory proteins to help the cells work longer. The goal is to find a safe dose and see if these engineered T-cells can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Houston Methodist Hospital

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Texas Children's Hospital

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.